Amlodipine Besylate And Benazepril Hydrochloride Capsule
NDC Package 51655-201-52

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings

Package Information

Amlodipine Besylate And Benazepril Hydrochloride capsules is amlodipine and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. This formulation utilizes a capsule delivery system. Marketed by Northwind Health Company, Llc, this product is identified by NDC 51655-201 and is authorized under FDA application ANDA077183.

Identification & Billing

NDC Package Code
51655-201-52
Package Description
30 CAPSULE in 1 BOTTLE, PLASTIC
Product Code
11-Digit Billing Format
51655020152
RxNorm Crosswalk
  • RxCUI: 898356 - amLODIPine besylate 5 MG / benazepril HCl 20 MG Oral Capsule
  • RxCUI: 898356 - amlodipine 5 MG / benazepril hydrochloride 20 MG Oral Capsule
  • RxCUI: 898356 - amlodipine (as amlodipine besylate) 5 MG / benazepril HCl 20 MG Oral Capsule
  • RxCUI: 898356 - Amlodipine 5 MG / BZP hydrochloride 20 MG Oral Capsule

Clinical Specifications

Proprietary Name
Amlodipine Besylate And Benazepril Hydrochloride
Non-Proprietary Name
Amlodipine Besylate And Benazepril Hydrochloride
Substance Name
Amlodipine Besylate; Benazepril Hydrochloride
Dosage Form
Capsule - A solid oral dosage form consisting of a shell and a filling. The shell is composed of a single sealed enclosure, or two halves that fit together and which are sometimes sealed with a band. Capsule shells may be made from gelatin, starch, or cellulose, or other suitable materials, may be soft or hard, and are filled with solid or liquid ingredients that can be poured or squeezed.
Administration Route
Oral - Administration to or by way of the mouth.
Usage Information
Amlodipine and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.

Regulatory & Marketing

Labeler Name
Northwind Health Company, Llc
Product Type
Human Prescription Drug
FDA Application #
ANDA077183
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-19-2023
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 51655-201-52 identifies a specific commercial package of 30 capsule in 1 bottle, plastic of Amlodipine Besylate And Benazepril Hydrochloride, a human prescription drug labeled by Northwind Health Company, Llc. This capsule is formulated for oral use and contains amlodipine besylate; benazepril hydrochloride as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Northwind Health Company, Llc on April 19, 2023. The current certification is valid through December 31, 2027.

How is this Northwind Health Company, Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 51655020152. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
51655-201-52
11-Digit CMS (5-4-2)
51655-0201-52

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.